The caspase activity assay demonstrated that primary AML and KG-1a cells treated with combination therapy exhibited significantly higher levels of caspase 3/7 activity compared to monotherapy (Fig. 5A and B). This evidence concerns the gene CASP3 and acute myeloid leukemia.